Related Experiment Video
Updated: Feb 17, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Zhuting Hu1, Patrick A Ott1,2,3, Catherine J Wu1,2,3,4
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Abstract:
Cancer vaccines, which are designed to amplify tumour-specific T cell responses through active immunization, have long been envisioned as a key tool of effective cancer immunotherapy. Despite a clear rationale for such vaccines, extensive past efforts were unsuccessful in mediating clinically relevant antitumour activity in humans. Recently, however, next-generation sequencing and novel bioinformatics tools have enabled the systematic discovery of tumour neoantigens, which are highly desirable immunogens because they arise from somatic mutations of the tumour and are therefore tumour specific. As a result of the diversity of tumour neoepitopes between individuals, the development of personalized cancer vaccines is warranted. Here, we review the emerging field of personalized cancer vaccination and discuss recent developments and future directions for this promising treatment strategy.
Insights
Personalized cancer vaccines, targeting unique tumor neoantigens, show promise for effective cancer immunotherapy. Advances in sequencing and bioinformatics enable tailored treatments, overcoming limitations of earlier cancer vaccine strategies.
Area of Science:
- Oncology
- Immunology
- Bioinformatics
Background:
- Cancer vaccines aim to boost T cell responses for immunotherapy but have historically shown limited clinical efficacy in humans.
- Tumor-specific neoantigens, arising from somatic mutations, are ideal targets for cancer vaccines due to their specificity.
- Individual variability in neoantigens necessitates personalized vaccine approaches.
Purpose of the Study:
- To review the emerging field of personalized cancer vaccination.
- To discuss recent advancements and future prospects in personalized cancer vaccine development.
Main Methods:
- Leveraging next-generation sequencing for systematic neoantigen discovery.
- Utilizing advanced bioinformatics tools for neoantigen identification and vaccine design.
Main Results:
- Neoantigen discovery has been significantly advanced by new sequencing and bioinformatics technologies.
- Personalized cancer vaccines are emerging as a promising strategy based on individual tumor neoantigens.
Conclusions:
- Personalized cancer vaccines represent a significant advancement in cancer immunotherapy.
- Future directions focus on optimizing personalized vaccine design and clinical application for improved antitumour activity.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

